Treating women with endocrine-resistant HR /HER2 advanced breast cancer

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen both groups reported similar quality of life

Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer

Improved survival outcomes in women with HER2-negative breast cancer after neoadjuvant chemotherapy

Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival

Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation

Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer

Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast and other cancers